advanced search
2023_Dec_DDL_Edinburgh_leaderboard

Tarsa Therapeutics

Tarsa Therapeutics developed TBRIA™, an oral formulation of calcitonin for postmenopausal osteoporosis. Rights to TBRIA have been acquired by R-Pharm JSC, whose US subsidiary is responsible for the continuing clinical development of TBRIA and subsequent regulatory submissions.


Headquarters
8 Penn Center
1628 John F Kennedy Boulevard
Suite 1400
Philadelphia
PA 19103-2124
United States

Phone / Contact

T: +1 267 273 7940
F: +1 267 273 7950

Authors and Contacts

Dr James Gilligan
Chief Scientific Officer
Tarsa Therapeutics

Article

EXPERT VIEW
Dr Nozer Mehta
TECHNOLOGIES & CLINICAL STUDIES FOR THE ORAL DELIVERY OF CALCITONIN
Nozer Mehta, James P Gilligan and William Stern summarise the different technologies that have been in development for oral delivery of peptides through the gastro-intestinal mucosal surfaces via the transcellular or the paracellular pathways and describe the results of several long-term clinical studies on the oral delivery of salmon calcitonin.
Top